Dr. Bearss will be the Chair of the “Drug Discovery for Neurodegenerative Diseases” session, on May 23.

BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics

Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET

This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)

Utah Business recently featured Halia Therapeutics co-founder David Bearss in their Founder Series

Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]

Halia Therapeutics announced the appointment of Dr. Margit M. Janát-Amsbury, MD, Ph.D. as the company’s Chief Medical Officer

HT-6184 is a novel NEK7/NLRP3 inhibitor

Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit. 

Halia Therapeutics New Leadership Team